⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Open Access

Generation of CAR-NK92mi cells as an off-the-shelf approach using nonviral minimized

Paula Alves Emmanuel Aragão Martín Bonamino

View Full Paper

Ask AI

Bookmark

Share

Key Points

To develop CAR-NK92mi cells using a nonviral method for enhanced immunotherapy applications.
Presented a nonviral minimized approach for the generation of CAR-NK92mi cells.
Focused on optimizing the cell engineering process for off-the-shelf use.
Conducted the study in collaboration with Bio-Manguinhos at Fundação Oswaldo Cruz.
Successfully generated CAR-NK92mi cells through a nonviral method, expanding potential therapeutic applications.
Demonstrated improved efficiency and viability of CAR-NK92mi cells for immunotherapy use.

Implication

Explores CAR-NK92mi cell generation methods, suggesting new immunotherapy options.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alves et al. (2026) studied this question.

synapsesocial.com/papers/69fece1db9154b0b82875c81 https://doi.org/10.35259/isi.2026_76201

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Generation of anti-GD2 CAR-T cellsOriginal Research · 2026
2Functional aplication of the iCasp9 suicide gene system as a safety mechanism for CAR-T CellsOriginal Research · 2026
3Evaluation of single-stranded DNA knock-in and base editing in combination with sleeping beauty transposon for a non-viral allogeneic 19BBz CAR-T generationOriginal Research · 2026
4Development of bispecific nanobody-derived CARs targeting b-cell leukemia markers: CD19, CD20, and CD22Original Research · 2026
5Cellular immunological mechanisms induced by messenger RNA vaccineOriginal Research · 2026

Development of targeted immunomodulatory VLPs to enhance antigen presentation and potentiate the antitumor immune response2026
Bio-Manguinhos and new generation of vaccines: consolidation of mRNA-LNP production and evaluation of critical quality attributes at pilot scale2026
Advancing the multivalent vaccine horizon: development of bicistronic self-amplifying RNA platforms for next-generation immunobiologicals2026